Literature DB >> 3524888

Effects of tumor growth on host defenses.

G J Cianciolo, R Snyderman.   

Abstract

Monocytes and macrophages play an important role in host defense against neoplasia. Studies from our and other laboratories have demonstrated that patients with a variety of cancers have a defect in monocyte chemotactic responses. Tumor-bearing mice are also inhibited in their ability to accumulate macrophages to inflammatory foci. We have shown that extracts prepared from murine tumors, as well as the plasma and urine of tumor-bearing mice, contain anti-inflammatory proteins which are antigenically and physicochemically related to the immunosuppressive retroviral envelope protein p15E. Similarly, proteins capable of inhibiting monocyte chemotactic responses are present in human cancerous effusions and can be specifically absorbed by monoclonal antibodies to p15E. Furthermore, we have demonstrated that human malignant and mitogen-transformed cells contain p15E-related antigens. These findings led us to propose a two stage model of tumorigenesis: the first stage involves neoplastic transformation of a cell while the second stage involves activation of a gene coding for a p15E-like protein which allows the transformed cell to escape immune surveillance and go on to become a tumor. Support for this model has come from recent studies which have identified within the human genome an endogenous retrovirus sequence whose envelope gene is partially homologous to a highly conserved region of p15E. Using a synthetic peptide, termed CKS-17, we have shown that this region may be responsible for many of the biological activities of p15E and is capable of suppressing lymphocyte and natural killer cell immune functions as well as those of monocytes and macrophages. Thus tumors may be capable of evading host defense mechanisms by activation of a normal gene related to the immunosuppressive retroviral protein p15E.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3524888     DOI: 10.1007/bf00049528

Source DB:  PubMed          Journal:  Cancer Metastasis Rev        ISSN: 0167-7659            Impact factor:   9.264


  47 in total

1.  Defective human mononuclear leukocyte chemotaxis as an index of host resistance to malignant melanoma.

Authors:  R H Rubin; A B Cosimi; E J Goetzl
Journal:  Clin Immunol Immunopathol       Date:  1976-11

2.  Assembly of type C oncornaviruses: a model.

Authors:  D P Bolognesi; R C Montelaro; H Frank; W Schäfer
Journal:  Science       Date:  1978-01-13       Impact factor: 47.728

3.  Molecular mechanisms in tumor-cell killing by activated macrophages.

Authors:  D O Adams; C F Nathan
Journal:  Immunol Today       Date:  1983-06

4.  Abnormal monocyte chemotactic response in cancer patients.

Authors:  D A Boetcher; E J Leonard
Journal:  J Natl Cancer Inst       Date:  1974-04       Impact factor: 13.506

5.  Modulation of spreading, adhesion and migration of peritoneal macrophages by a low molecular weight factor extracted from mouse tumors.

Authors:  W D Cantarow; H T Cheung; G Sundharadas
Journal:  J Reticuloendothel Soc       Date:  1978-12

6.  Characterization of human endogenous retroviral envelope RNA transcripts.

Authors:  A B Rabson; Y Hamagishi; P E Steele; M Tykocinski; M A Martin
Journal:  J Virol       Date:  1985-10       Impact factor: 5.103

7.  Macrophage function in tumor-bearing mice: evidence for lactic dehydrogenase-elevating virus-associated changes.

Authors:  M M Stevenson; J C Rees; M S Meltzer
Journal:  J Immunol       Date:  1980-06       Impact factor: 5.422

8.  Monocyte responsiveness to chemotactic stimuli is a property of a subpopulation of cells that can respond to multiple chemoattractants.

Authors:  G J Cianciolo; R Snyderman
Journal:  J Clin Invest       Date:  1981-01       Impact factor: 14.808

9.  Nucleotide sequence of a full-length human endogenous retroviral segment.

Authors:  R Repaske; P E Steele; R R O'Neill; A B Rabson; M A Martin
Journal:  J Virol       Date:  1985-06       Impact factor: 5.103

10.  Macrophages and resistance to tumors. IV. Influence of age on susceptibility of mice to anti-inflammatory and antimacrophage effects of tumor cell products.

Authors:  M Nelson; D S Nelson
Journal:  J Natl Cancer Inst       Date:  1980-10       Impact factor: 13.506

View more
  7 in total

1.  Functional variations in liver tissue during the implantation process of metastatic tumour cells.

Authors:  F Vidal-Vanaclocha; A Alonso-Varona; R Ayala; E Barberá-Guillem
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1990

2.  Suppression of tumor formation in vivo by expression of the JE gene in malignant cells.

Authors:  B J Rollins; M E Sunday
Journal:  Mol Cell Biol       Date:  1991-06       Impact factor: 4.272

3.  Suppressive effect on polyclonal B-cell activation of a synthetic peptide homologous to a transmembrane component of oncogenic retroviruses.

Authors:  M Mitani; G J Cianciolo; R Snyderman; M Yasuda; R A Good; N K Day
Journal:  Proc Natl Acad Sci U S A       Date:  1987-01       Impact factor: 11.205

Review 4.  Organ specificity of tumor metastasis: role of preferential adhesion, invasion and growth of malignant cells at specific secondary sites.

Authors:  G L Nicolson
Journal:  Cancer Metastasis Rev       Date:  1988-06       Impact factor: 9.264

Review 5.  Paracrine and autocrine growth mechanisms in tumor metastasis to specific sites with particular emphasis on brain and lung metastasis.

Authors:  G L Nicolson
Journal:  Cancer Metastasis Rev       Date:  1993-09       Impact factor: 9.264

6.  The immunodominant major histocompatibility complex class I-restricted antigen of a murine colon tumor derives from an endogenous retroviral gene product.

Authors:  A Y Huang; P H Gulden; A S Woods; M C Thomas; C D Tong; W Wang; V H Engelhard; G Pasternack; R Cotter; D Hunt; D M Pardoll; E M Jaffee
Journal:  Proc Natl Acad Sci U S A       Date:  1996-09-03       Impact factor: 11.205

7.  Generation of lymphokine-activated killer cells in human ovarian carcinoma ascitic fluid: identification of transforming growth factor-beta as a suppressive factor.

Authors:  H Hirte; D A Clark
Journal:  Cancer Immunol Immunother       Date:  1991       Impact factor: 6.968

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.